

**Book by August 23 &
Save up to \$300**

October 29-31, 2019 | Boston, MA, USA

www.inflammasome-therapeutics.com



Inflammasome Therapeutics Summit

Targeting the Inflammasome to Develop Clinically Effective Therapeutics

21 Expert Speakers Include:



Ariel Feldstein
Professor &
Chief, Pediatric
Gastroenterology &
Founder
**UC San Diego &
Jecure Therapeutics**



Rebecca Coll
Principle
Investigator
**Queen's University
Belfast**



Steve Glover
Co-founder & Chief
Executive Officer
Zyversa



Alan Watt
Chief Scientific
Officer
Nodthera




Kate Fitzgerald
Principal
Investigator
**Umass Medical
School**



Erik Hett
Head Experimental
& Chemical Biology
& Director
Merck



John Wing
Senior Medical
Science Liaison
PTC Therapeutics



Changyun Hu
Senior Scientist
**Jounce
Therapeutics**



Russell Wyborski
Associate
Director, Technical
Operations
BioMotiv

Industry Partner: 
THERAPEUTICS™

Welcome to the Inflammasome Therapeutics Summit

Built with **Pfizer, Nodthera & Jecure Therapeutics** the inaugural industry-focused Inflammasome Therapeutics Summit (ITS) will **solve the challenges in targeting the inflammasome to develop clinically effective therapeutics**.

This summit is the first of its kind, uniting thought leaders in inflammasome drug development to discuss their challenges and opportunities, with the aim to transform and accelerate the field.

This discussion-led forum will enable you to:

- **Deepen your biological understanding** of how the inflammasome is activated and regulated at a cellular level
- Identify novel inflammasome pathways focussing not only on NLRP3 but **looking beyond and outside of this exciting pathway**
- Determine which diseases the inflammasome is driving to identify have **the most therapeutic potential commercially and clinically**

Join your peers at this definitive forum to exchange novel ideas, gather lessons learned and create new connections. Don't miss your opportunity to **be a part of the force accelerating the development of inflammasome therapeutics**.

Hear what previous Hanson Wade attendees have to say

“I was impressed by many of the speakers and learnt a significant amount, which I was able to bring back to our discovery team”

Eisai

“One of the best CNS therapeutics meetings to attend”

P2D Bioscience

“Great list of speakers, nice variety of activities. Perfect size to meet everyone and feel comfortable engaging others”

Novartis

Your Top 5 Reasons to Attend ITS



Learn how other companies are tackling the preclinical model challenge by further exploring *in vitro* and *in vivo* models of NLRP3 inflammasome activation and improve translation into clinical trials



Review the basic biology of the inflammasome and delving deeper into the mechanism of action of the NLRP3 inflammasome to **bridge the gap between discovery and drug development**



Explore outside of the NLRP3 inflammasome with insights into NLRP1 mechanism of action and using inflammasome proteins as a biomarker to **broaden the scope of the inflammasome**



Share your cutting-edge research in our scientific poster session, this allows you to connect with your peers in a relaxed atmosphere and **gain feedback on your latest developments**



Gain an understanding of the various targets companies are focusing on and get a better understanding on the inflammasome landscape and the exciting work being carried out


Your 21 Expert Speakers




Alan Watt
Chief Scientific
Officer
Nodthera



Ariel Feldstein
Professor &
Chief, Pediatric
Gastroenterology &
Founder
**UC San Diego
& Jecure
Therapeutics**



Bernat Baeza-Raja
Senior Scientist
**Second Genome,
Inc**



Changyun Hu
Senior Scientist
**Jounce
Therapeutics**



Chris Gabel
Vice President,
Biology
Nodthera



CJ Barnum
Director,
Neurosciences
INmune Bio



Daniel Bachovchin
Assistant Professor
**Memorial Sloan
Kettering Cancer
Center**



Davide Povero
Senior Research
Scientist, Department
of Biochemistry &
Molecular Biology,
Mayo Clinic
**Previous Jecure
Therapeutics Employee**



Erik Hett
Head Experimental
& Chemical Biology
Merck



Hao Wu
Professor
**Harvard Medical
School**



Humayun sharif
Research Fellow
**Harvard Medical
School**



John Wing
Senior Medical
Science Liaison
PTC Therapeutics



**Juan Pablo De
Rivero Vaccari**
Research Assistant
Professor
**University of Miami
Miller School of
Medicine**



Kate Fitzgerald
Principal Investigator
**Umass Medical
School**



Marcelo Hill
Chief Scientific
Officer & Founder
**ARDAN
ImmunoPharma**



Matt Cooper
Chief Executive
Officer & Co-
Founder,
Inflazome



Matthew Havrda
Assistant Professor
of Molecular &
Systems Biology
**Dartmouth School
of Medicine**



**Rachel
Mak'Anyengo**
Product Manager
Novartis



Rebecca Coll
Principle Investigator
**Queen's University
Belfast**



Russell Wyborski
Associate
Director, Technical
Operations
BioMotiv



Steve Glover
Co-founder & Chief
Executive Officer
**ZyVersa
Therapeutics**

Conference Day One

Wednesday October 30, 2019

Alan Watt
 Chief Scientific
 Officer
Nodthera

8.50 Chair's Opening Remarks

Reviewing the Basic Biology & Mechanisms of Action for the Inflammasome

Rebecca Coll
 Principle Investigator
**Queen's University
 Belfast**

9.00 Targeting the NLRP3 Inflammasome for the Treatment of Inflammatory Diseases

- NLRP3 signalling pathways
- NLRP3-associated inflammatory diseases
- Rationale for the development of specific NLRP3 inhibitors
- Mechanism of action of the small-molecule NLRP3 inhibitor MCC950

Chris Gabel
 Vice President,
 Biology
Nodthera

9.30 The Discovery & Characterisation of a Novel Chemotype for Enhanced NLRP3 Inflammasome Inhibition & Tissue Penetration

- Ester prodrugs provide unprecedented potency against NLRP3-mediated IL-1 β production in cellular assays
- Pharmacodynamic impact demonstrated in a proprietary humanised carboxylesterase transgenic mouse
- In a brain perfusion model, ester-containing compounds are highly tissue penetrant

Kate Fitzgerald
 Principal Investigator
**Umass Medical
 School**

10.00 Inflammasomes in Infection & Inflammation

- Explore basic mechanisms of inflammasome activation
- Define new role for AIM2 in melanoma
- Mechanisms turning off inflammasome responses



10.30 Speed Networking

This session is the ideal opportunity to get face-to-face time with many of the brightest minds working in the Inflammasome field and establish meaningful business relationships to pursue for the rest of the conference.

11.30 Morning Refreshments & Networking

Reviewing the Basic Biology & Mechanisms of Action for the Inflammasome

Erik Hett
 Head of Experimental
 & Chemical Biology
Merck

12.00 A Chemical Approach to Map Protein Interactions

Hao Wu
 Professor
**Harvard Medical
 School**

12.30 Structure of The NLRP3-NEK7 Complex & the Mechanism of NLRP3 Activation


- Structure of the NLRP3-NEK7 complex (published)
- Ongoing elucidation on the mechanism of NLRP3 activation
- Mechanism of small molecule inhibition

1.00 Lunch & Networking

Assessing Preclinical Animal Models for Improved Translation into Clinical Trials

Steve Glover Co-founder & Chief Executive Officer ZyVersa Therapeutics	2.00 How Much Time & Effort Should any Company be Spending on Preclinical Models - Transitioning from translational science to commercialization - Choosing the right animal models for both scientific and commercialization purposes - Projecting future potential indications while aligning with your near term preclinical requirements
Alan Watt Chief Scientific Officer Nodthera	2.30 The Discovery & Development of NT-0167, a Potent, Selective NLRP3 Inflammasome Inhibitor - NT-0167 demonstrates excellent in vitro and <i>in vivo</i> potency in assays driven NLRP3-mediated IL-1β production - Characterization in an animal model of Muckle Wells Syndrome (hNLRP3 D305N syntenic mouse) shows excellent efficacy - Compound is safe to large margins in toxicological studies
	3.00 Afternoon Refreshments & Networking

Assessing Preclinical Animal Models for Improved Translation into Clinical Trials

Davide Povero Senior Research Scientist, Department of Biochemistry & Molecular Biology, Mayo Clinic Previous Jecure Therapeutics Employee	4.00 Molecular Signals that Activate NLRP3 Inflammasome & Trigger Sterile Inflammation - Role of NLRP3 activation during sterile inflammation - Danger-associated molecular patterns (DAMPs) that trigger the activation of NLRP3 inflammasome - Experimental in vitro and <i>in vivo</i> models of NLRP3 inflammasome activation via different stimuli
Rachel Mak'Anyengo Product Manager Novartis	4.30 NLRP3-Dependent IL-1β inhibits CD103+ Dendritic Cell Differentiation in the Gut - Inflammatory bowel disease (IBD) is associated with enhanced levels of the IL-1 family cytokines IL-1β and IL-18, which are activated by the Nlrp3 inflammasome - Here, we investigated the role of inflammasome-driven cytokine release on T cell polarization and DC differentiation in steady state and T cell transfer colitis
	5.00 Chairs Closing Remarks
	5.10 Scientific Poster Session After the formal presentations have finished, the learning and networking carries on. The Poster Session allows you to connect with your peers in a relaxed atmosphere and continue to forge new and existing relationships. During this session scientific posters will be presented on the latest advancements in the inflammasome field

Well organized, great list of speakers, nice variety of activities. Perfect size to meet everyone and feel comfortable engaging others

Novartis

Conference Day Two

Thursday October 31, 2019

Benchmarking the Specific Diseases the Inflammasome can Target

Matt Cooper Chief Executive Officer & Co-Founder, Inflazome	8.00 Pharmacology Inhibition of the NLRP3 Inflammasome - The early breakthroughs - Innate immunity, infection & chronic inflammation - Drug development - Clinical utility in CNS & peripheral diseases - Inzomelid & Somalix
Russell Wyborski Associate Director, Technical Operations BioMotiv	8.30 Fbx03 Inhibitor KT-1002 for the Treatment of Inflammatory Bowel Disease - Fbx03 involvement in the release of cytokines - Connection of Fbx03 to IBD - Development of KT-1002 - Challenges faced with First-in-Class E3 Ligase inhibitor
Ariel Feldstein Professor & Chief, Pediatric Gastroenterology & Founder UC San Diego & Jecure Therapeutics	9.00 Inflammasome Modulation to Treat NASH & Liver Fibrosis - Describe experimental and human evidence for the role of NLRP3 inflammasome in NASH development - Review mechanisms of cell specific activation of the NLRP3 inflammasome in liver inflammation and fibrosis - Dissect the IL-1 dependent and -independent mechanisms of liver injury triggered by NLRP3 activation
Matthew Havrda Assistant Professor of Molecular & Systems Biology Dartmouth School of Medicine	9.30 Characterizing NLRP3 in Parkinson's Disease - Evidence supporting a role for NLRP3 in toxicant based mouse models of Parkinson's disease. - Histopathologic analysis of NLRP3 expression in Parkinson's patients. - Evaluation of plasma-born inflammasome related proteins in Parkinson's patients
	10.00 Morning Refreshments & Networking

Too Much Choice? Delving into Target Identification for the Inflammasome

Marcelo Hill Chief Scientific Officer & Founder ARDAN ImmunoPharma	11.00 Targeting Ion Channels to Trigger Inflammasome-Dependent Tumor Immunity - The cation channel TMEM176B inhibits the NLRP3 inflammasome by controlling cytosolic Ca²⁺. - Lack of Tmem176b enhances antitumor immunity via the caspase-1/IL-1b pathway - Human tumors responding to immune checkpoint blockade display an inflammasome-activated signature - A TMEM176B inhibitor improves the antitumor activity of immune checkpoint blockade
Changyun Hu Senior Scientist Jounce Therapeutics	11.30 NLRP3 Inflammasome, Chemotaxis & Autoimmune Disease - NLRP3 inflammasome and human diseases - Current therapeutic targeting NLRP3 inflammasome - NLRP3 inflammasome controls autoimmunity through regulating the chemotaxis of autoreactive immune cells. - Perspective on NLRP3 inflammasome pathway as a therapeutic target for autoimmune diseases
CJ Barnum Director, Neurosciences INmune Bio	12.00 Approaching Neurodegenerative Disease as an Immunological Disease - Chronic inflammation starts early, is the root cause of sickness syndromes, and promulgates the proteinopathies observed in neurodegenerative diseases such as Parkinson's and Alzheimer's disease - Effectively targeting chronic inflammation requires threading the needle between a sufficiently potent anti-inflammatory treatment that is not immuno- nor glial- suppressive - Inflammatory biomarkers will play an important role in determining when and how these therapies should be used

Improving Innovation in Clinical Trial Design to Enhance Execution



12.30 Roundtable Session: Designing Phase II Studies

This round table session will host interactive discussions amongst your tables and allow you to share your opinions with your peers on determining effective, it will involve assessing first indications for putting new compounds in to a phase II Study

1.00 Lunch & Networking

Looking Outside of the NLRP3 Inflammasome

Daniel Bachovchin
 Assistant Professor
**Memorial Sloan
 Kettering Cancer
 Center**

2.00 Activation of the NLRP1 Inflammasome

- Insights into the mechanism of DPP8/9 inhibitor-induced pyroptosis
- ASC-independence of CARD8 and ASC-dependence of NLRP1
- Requirement of human caspase-1 autoproteolysis for inflammasome activation

Bernat Baeza-Raja
 Senior Scientist
Second Genome, Inc

2.30 Targeting the Inflammasome through P2X7 receptor & Its Potential Implications for NASH Therapy

- Exploring the role of P2RX7 in NASH
- Effects of P2RX7 inhibition in liver cells and animal models with liver injury
- Clinical development and challenges of the first-in-class P2RX7 inhibitor, SGM-1019

**Juan Pablo De
 Rivero Vaccari**
 Research Assistant
 Professor
**University of Miami
 Miller School of
 Medicine**

3.00 Inflammasome Proteins as Biomarkers

- Inflammasome proteins can be used as diagnostic biomarkers in a variety of diseases and conditions such as mild cognitive impairment, multiple sclerosis, traumatic brain injury and stroke
- Inflammasome proteins can be used as biomarkers to monitor disease severity
- Inflammasome proteins can be used as prognostic biomarkers of acute injury outcome

3.30 Afternoon Break & Networking

Looking Outside of the NLRP3 Inflammasome

John Wing
 Senior Medical
 Science Liaison
PTC Therapeutics

4.00 The Immune Response in Duchenne Muscular Dystrophy: Current Therapeutic Approaches & Potential Translational Opportunities

- Discussion of the immune response in the pathogenesis of Duchenne Muscular Dystrophy
- The role of immunomodulation in DMD: the benefits of corticosteroids and the development of future and combination therapies
- What are the current translational opportunities that would support future therapies in DMD?

John Wing
 Senior Medical
 Science Liaison
PTC Therapeutics

4.30 Mastermind Session: Discussing the Potential of Inflammasome Therapeutics in Combination

- The complexity of the immune response in DMD: understanding the balance in the regulation of immunity
- Current therapeutic approaches in DMD
- Lessons learned from other inflammatory disease: Translational Medicine

Alan Watt
 Chief Scientific
 Officer
Nodthera

5.00 Chair's Closing Remarks

Pre Conference Workshop Day Tuesday October 29, 2019

Workshop A

9:00 – 12:00

Delving Further into the Protein & Crystal Structures of Inflammasomes

Understanding the structure of key signaling molecules in the inflammasome pathway and understanding where the binding pockets are is key to advancing pre-clinical and clinical development of the inflammasome. Once the drug pockets are known, the location of where the drug can bind is known, hence, optimizing the drug. Exploring the protein structure of the inflammasome in its activated state is also key to getting a more efficacious drug.

This workshop will cover:

- Challenges of NLRP3 protein purification
- Cryo-EM data collection
- Data analysis and model building
- Challenges and considerations for NLRP3 drug discovery

Workshop Leader



Humayun Sharif
 Research Fellow
 Harvard Medical School

Workshop B

1:00 – 4.00

How do Inflammasome Inhibitors Work? Exploring the Mechanisms of Action of Inflammasome Formation & Inhibition

The inflammasome is a large protein complex that assembles and then activates cytokine signalling and cell death. Many compounds have been identified that can inhibit inflammasome signalling, however it is often not clear exactly how these compounds are working.

This workshop will cover the following questions:

- Are they binding to specific components of the inflammasome complex and preventing it from forming?
- Are they working upstream of the complex?
- Are they working indirectly through a different molecular target within the cell?
- What are the challenges and techniques involved in identifying the mechanism of action of inflammasome inhibitors?

This workshop aims to getting one step closer to answering these questions.

Workshop Leader



Rebecca Coll
 Principle Investigator,
 Wellcome-Wolfson Institute
 for Experimental Medicine
 Queen's University
 Belfast



Matthew Havrda
 Assistant Professor of
 Molecular & Systems
 Biology
 Dartmouth School of
 Medicine

Partnership Opportunities

Are you looking to work with drug developers, that are developing inflammasome therapeutics?

Partnering with the Inflammasome Therapeutics Summit is your opportunity to demonstrate your expertise in inflammasome drug development and elevate your company's standing and influence within the community.


Your brand, your message, your reputation showcased in front of the leading experts in the field of inflammasome drug development.

This forum will be a unique platform for you to demonstrate how your company can enable drug developers to overcome the barriers preventing the development of truly curative inflammasome therapeutics. This could involve speaking on the agenda, hosting networking sessions or exhibiting. **We'll work with you to build a bespoke partnership** to ensure that you meet your 2019 business objectives.

Get in touch today to learn more about how we can support your business objectives within the inflammasome field.

Email us at sponsor@hansonwade.com

Audience Seniority*




C-Level: 26%

Vice President: 10%

Senior Director/
Director: 40%

Scientist: 24%

Attending Companies*



Pharma
Biotech
Solution Providers
Academia

*Based on previous Hansonwade statistics

ZyVersa
THERAPEUTICS™

Industry Partner:

ZyVersa is a clinical stage company developing first-in-class drugs for inflammatory and renal diseases. Development includes a novel inflammasome inhibitor, IC 100, and a cholesterol efflux mediator for FSGS, an orphan renal disease.

IC 100 is a mAb that uniquely inhibits the ASC component of multiple inflammasomes. As numerous inflammatory diseases are associated with activation of more than one inflammasome, IC 100 is expected to have a therapeutic effect in a broad group of disorders.

www.zyversa.com

Contact us today to find out how we can help achieve your 2019 business goals faster



Frank Plowden
Partnerships Manager
Tel: +1 617 455 4188
Email: sponsor@hansonwade.com

Ready to Register?

3 Easy Ways To Book

 www.inflammasome-therapeutics.com

 Tel: +1 617 455 4188

 Email: register@hansonwade.com

Top 3 Reasons to Attend:

- ① Bridge the gap between discovery and drug development as we bring together industry and academia
- ② Gain an understanding of the landscape of inflammasome therapeutics and the exciting future of the field
- ③ Learn from industry leaders and the lessons they have learned during their inflammasome drug development

Secure Your Place

Industry Pricing	Register & Pay before Friday August 23	Standard Prices
Conference Only	\$1,999 (Save \$300)	\$2,299
Conference + Workshops	\$2,899 (Save \$300)	\$3,199


Academic Pricing	Register & Pay before Friday August 23	Standard Prices
Conference Only	\$1,309 (Save \$300)	\$1,609
Conference + Workshops	\$1,939 (Save \$300)	\$2,239

Team Discounts*

- **10% discount – 3 delegates**
- **15% discount – 4 delegates**
- **20% discount – 5 or more delegates**

*Please note that discounts are only valid when three or more delegates from one company book and pay at the same time.

Discounts cannot be used in conjunction with any other offer or discount. Only one discount offer may be applied to the current pricing rate. Contact: register@hansonwade.com



VENUE

The Revere Boston Common
 200 Stuart Street Boston,
 Massachusetts, 02116

For further information or assistance, please visit
www.reverehotel.com

TERMS & CONDITIONS

Full payment is due on registration. Cancellation and Substitution Policy: Cancellations must be received in writing. If the cancellation is received more than 14 days before the conference attendees will receive a full credit to a future conference. Cancellations received 14 days or less (including the fourteenth day) prior to the conference will be liable for the full fee. A substitution from the same organization can be made at any time.

Changes to Conference & Agenda: Hanson Wade reserves the right to postpone or cancel an event, to change the location or alter the advertised speakers. Hanson Wade is not responsible for any loss or damage or costs incurred as a result of substitution, alteration, postponement or cancellation of an event for any reason and including causes beyond its control including without limitation, acts of God, natural disasters, sabotage, accident, trade or industrial disputes, terrorism or hostilities.

Data Protection: The personal information shown and/or provided by you will be held in a database. It may be used to keep you up to date with developments in your industry. Sometimes your details may be obtained or made available to third parties for marketing purposes. If you do not wish your details to be used for this purpose, please write to: Database Manager, Hanson Wade, Suite A, 6 Honduras Street, London EC1Y 0TH

Code: 000